

Macrocycles that inhibit the binding between heat shock protein 90 and TPR-containing proteins

Veronica C. Ardi^b, Leslie D. Alexander^b, Victoria A. Johnson^b, and Shelli R. McAlpine^{a*}

^a School of Chemistry, 219 Dalton, Gate 2 High Street, Kensington, NSW, 2052, Australia. *Corresponding author.


^b Department of Chemistry and Biochemistry, 5500 Campanile Road, San Diego State University, San Diego, CA 92182-1030.

Contents:


Title page and table of contents.....	S1
Supplemental figures.....	S3
General synthesis of biotinylated peptides.....	S4
Methods of chromatographic purity.....	S5
Spectral data for compounds.....	Sx
¹ H NMR Double Deprotected Pentapeptide 1-T-II: <i>HO-Leu-Phe-Lys(Cbz)-Val-Leu-NH₂</i>	S8
LCMS Double Deprotected Pentapeptide 1-T-II: <i>HO-Leu-Phe-Lys(Cbz)-Val-Leu-NH₂</i>	S9
¹ H NMR Cyclized Pentapeptide 1-T-II: <i>Phe-Lys(Cbz)-Val-Leu-Leu</i>	S10
LCMS Cyclized Pentapeptide 1-T-II: <i>Phe-Lys(Cbz)-Val-Leu-Leu</i>	S11
HPLC Cyclized Pentapeptide 1-T-II: <i>Phe-Lys(Cbz)-Val-Leu-Leu</i>	S12
¹ H NMR Cyclized Pentapeptide 1-T-II: <i>Phe-Lys-Val-Leu-Leu</i>	S13
LCMS Cyclized Pentapeptide 1-T-II: <i>Phe-Lys-Val-Leu-Leu</i>	S14
HPLC Cyclized Pentapeptide 1-T-II: <i>Phe-Lys-Val-Leu-Leu</i>	S15
¹ H NMR Biotinylated Pentapeptide 1-T-II: <i>Phe-Lys(Peg-biotin)-Val-Leu-Leu</i>	S16
LCMS Biotinylated Pentapeptide 1-T-II: <i>Phe-Lys(Peg-biotin)-Val-Leu-Leu</i>	S17
HPLC Biotinylated Pentapeptide 1-T-II: <i>Phe-Lys(Peg-biotin)-Val-Leu-Leu</i>	S18
¹ H NMR Double Deprotected Pentapeptide 1-T-III: <i>HO-Leu-Phe-Leu-Lys(Cbz)-Leu-NH₂</i>	S19
LCMS Double Deprotected Pentapeptide 1-T-III: <i>HO-Leu-Phe-Leu-Lys(Cbz)-Leu-NH₂</i>	S20
¹ H NMR Cyclized Pentapeptide 1-T-III: <i>Phe-Leu-Lys(Cbz)-Leu-Leu</i>	S21
LCMS Cyclized Pentapeptide 1-T-III: <i>Phe-Leu-Lys(Cbz)-Leu-Leu</i>	S22
HPLC Cyclized Pentapeptide 1-T-III: <i>Phe-Leu-Lys(Cbz)-Leu-Leu</i>	S23
¹ H NMR Cyclized Pentapeptide 1-T-III: <i>Phe-Leu-Lys-Leu-Leu</i>	S22
LCMS Cyclized Pentapeptide 1-T-III: <i>Phe-Leu-Lys-Leu-Leu</i>	S25
HPLC Cyclized Pentapeptide 1-T-III: <i>Phe-Leu-Lys-Leu-Leu</i>	S26
¹ H NMR Biotinylated Pentapeptide 1-T-III: <i>Phe-Leu-Lys(Peg-biotin)-Leu-Leu</i>	S27
LCMS Double Deprotected Pentapeptide 2-T-I: <i>(2R, 3R)(2S,3S) β-OH-Phe-Leu-N-Me-Val-D-Leu-D-Phe</i>	S28
¹ H NMR Cyclized Pentapeptide 2-T-I: <i>(2R, 3R) β-OH-Phe-Leu-N-Me-Val-D-Leu-D-Phe</i>	S29
LCMS Cyclized Pentapeptide 2-T-I: <i>(2R, 3R) β-OH-Phe-Leu-N-Me-Val-D-Leu-D-Phe</i>	S30
LCMS Biotinylated Pentapeptide 2-T-I: <i>(2R, 3R) β-O(Peg-biotin)-Phe-Leu-N-Me-Val-D-Leu-D-Phe</i>	S31
¹ H NMR Cyclized Pentapeptide 2-T-II: <i>(2R, 3R)(2S,3S) β-OBn-Phe-Lys(Boc)-N-Me-Val-D-Leu-D-Phe</i>	S32
LCMS Cyclized Pentapeptide 2-T-II: <i>(2R, 3R)(2S,3S) β-OBn-Phe-Lys(Boc)-N-Me-Val-D-Leu-D-Phe</i>	S33
LCMS Cyclized Pentapeptide 2-T-II: <i>(2R, 3R)(2S,3S) β-OBn-Phe-Lys-N-Me-Val-D-Leu-D-Phe</i>	S34
¹ H NMR Biotinylated 2-T-II: <i>(2R, 3R)(2S,3S) β-OBn-Phe-Lys(peg-biotin)-N-Me-Val-D-Leu-D-Phe</i>	S35
LCMS Biotinylated 2-T-II: <i>(2R, 3R)(2S,3S) β-OBn-Phe-Lys(peg-biotin)-N-Me-Val-D-Leu-D-Phe</i>	S36
LCMS Linear Pentapeptide 2-T-III: <i>OH-Leu-N-Me-Lys(Boc)-D-Leu-D-Phe-(2R,3R)(2S,3S)-β-OH-Phe-NH₂</i>	S37

¹ H NMR Cyclized Pentapeptide 2-T-III: (2 <i>R</i> ,3 <i>R</i>),(2 <i>S</i> ,3 <i>S</i>) β- <i>OH</i> -Phe-Leu- <i>N</i> -Me-Lys(Boc)- <i>D</i> -Leu- <i>D</i> -Phe	S38
LCMS Cyclized Pentapeptide 2-T-III: (2 <i>R</i> ,3 <i>R</i>),(2 <i>S</i> ,3 <i>S</i>) β- <i>OH</i> -Phe-Leu- <i>N</i> -Me-Lys(Boc)- <i>D</i> -Leu- <i>D</i> -Phe	S39
¹ H NMR Cyclized Pentapeptide 2-T-III: (2 <i>R</i> ,3 <i>R</i>),(2 <i>S</i> ,3 <i>S</i>) β- <i>OBn</i> -Phe-Leu- <i>N</i> -Me-Lys(Boc)- <i>D</i> -Leu- <i>D</i> -Phe	S40
LCMS Cyclized Pentapeptide 2-T-III: (2 <i>R</i> ,3 <i>R</i>),(2 <i>S</i> ,3 <i>S</i>) β- <i>OBn</i> -Phe-Leu- <i>N</i> -Me-Lys(Boc)- <i>D</i> -Leu- <i>D</i> -Phe	S41
¹ H NMR Biotinylated Pentapeptide 2-T-III: (2 <i>R</i> ,3 <i>R</i>)β- <i>OBn</i> -Phe-Leu- <i>N</i> Me-Lys(Biotin)- <i>D</i> Leu	S42
LCMS Biotinylated Pentapeptide 2-T-III: (2 <i>R</i> ,3 <i>R</i>)β- <i>OBn</i> -Phe-Leu- <i>N</i> -Me-Lys(Peg-biotin)- <i>D</i> -Leu- <i>D</i> -Phe	S43
HPLC Biotinylated Pentapeptide 2-T-III: (2 <i>R</i> ,3 <i>R</i>)β- <i>OBn</i> -Phe-Leu- <i>N</i> -Me-Lys(Peg-biotin)- <i>D</i> -Leu- <i>D</i> -Phe	S44


SUPPLEMENTAL FIGURES



SI Figure 1. Competitive binding assays between tagged and untagged compounds. Increasing concentrations of 1 and 2 compete with 1-T-IV and 2-T-III, respectively, for binding to Hsp90.




SI Figure 2. Depletion or overexpression of Hsp90. a) HeLa cells were transfected with 1nM of si-control (Qiagen Ctl_AllStars_1) or 0.5nM of si-Hsp90 α (AACCCTGACCATTCCATTATT) and 0.5nM of si-Hsp90 β (CAAGAATGATAAGGCAGTTAA) for 48 hours. Down-regulation of Hsp90 was confirmed by Western blot. b) HeLa cells were transfected with pCMV (control) or pCMV-Hsp90 plasmid for 24 hours. Overexpression of Hsp90 was confirmed by Western blot. GAPDH was WB for loading control analyses.



SI Figure 3. Western blots from co-immunoprecipitations using compound 1 and 2-treated cell lysates and antibody for Hsp90. Bands were analyzed using Image J densitometric software. The amount of Hop in each

lane was normalized to Hsp90. Graphs shown in main manuscript were produced calculating the amount of Hop in compound co-IPs compared to DMSO controls.



SI Figure 4. Competitive binding affinity of compound 1-Tag-III and compound 2 with Hsp90. Purified, native Hsp90 (Stressgen) was incubated in PBS (without calcium or magnesium) with 10 μM biotinylated compound 1-Tag-III for 1 h at room temp, and then incubated with 0-25 μM of compound 2 for 1 h at room temp. Streptavidin beads were added and incubated for 30 min at room temp followed by removal of the unbound supernatant. The beads were washed four times with PBS and heated for 15 min at 100 °C in SDS-PAGE sample buffer. Samples were analyzed on SDS page protein gels (Invitrogen), and western blots were done using Hsp90 antibodies. Bands in the western blots were quantified using Image J, and the percentage of Hsp90 still bound to the beads was calculated. This experiment was run two independent times. It was found that compound 2 inhibited binding of compound 1-Tag-III with an IC₅₀ of 5.2 μM, thus, confirming our findings that compound 1 and 2 both bind to Hsp90 at the same binding site.

GENERAL SYNTHESIS OF BIOTINYLATED PEPTIDES

General solid phase synthesis remarks

Stepwise solid phase peptide synthesis was performed in a polypropylene solid-phase extraction cartridge fitted with a 20 μM polyethylene frit purchased from Applied Separations (Allentown, PA). 2-Chlorotrityl resins were purchased in pre-loaded form with L-Phe, D-Phe, or L-Leu. Resins were swelled in DMF for 30 min prior to assembly of the linear five-residue peptide sequence. Solid-phase syntheses were performed on a 0.5-0.8 mmol scale based on resin-loading. All operations were performed at room temperature under open atmosphere unless stated otherwise.

General solid phase peptide synthesis

Fmoc-protected amino acids were coupled using 3 equiv of amino acid, 3 equiv of 1-hydroxybenzotriazole, and 6 equiv of diisopropylcarbodiimide. Couplings were performed in DMF at 0.2 M with respect to the incoming Fmoc-protected amino acid. Couplings were allowed to proceed for a minimum of 2 h, and were assayed via ninhydrin test to verify completion. Once complete, the coupling reaction solution was drained, and the resin subjected to Fmoc deprotection. (Note: Fmoc and N-methyl amino acids are coupled according to the cycle above, however for subsequent coupling onto the secondary amino terminus, 1-hydroxybenzotriazole was substituted with 1-hydroxy-7-azabenzotriazole and the coupling was allowed to proceed overnight).

General solid phase amine deprotection

Following coupling completion, the peptide-resin was treated as follows for removal of the Fmoc protecting group: DMF wash (3 x 1 min), 20% Piperidine/DMF (1 x 5 min), 20% Piperidine/DMF (1 x 10 min), DMF wash (2 x 1 min), IPA wash (1 x 1 min), DMF wash (1 x 1 min), IPA (1 x 1 min), DMF (3 x 1 min). A ninhydrin test was performed to verify completion.

General N-terminal solid phase amine deprotection

Once the final N-terminal amino acid residue had been coupled, the peptide-resin was treated as follows for removal of the Fmoc protecting group: DMF wash (3 x 1 min), 20% Piperidine/DMF (1 x 5 min), 20% Piperidine/DMF (1 x 10 min), DMF wash (3 x 1 min), IPA wash (3 x 1 min), MeOH (3 x 1 min). The fully-assembled peptide-resin was then drained and dried in vacuo overnight.

Cleavage of linear peptide

The full-length, linear peptide was cleaved from the resin by swelling and shaking the peptide-resin for 24 h in a 1:1 (v/v) 2,2,2-trifluoroethanol/ CH_2Cl_2 (10 volumes/gram of dried resin). The cleavage solution was filtered through a Buchner filter, and the drained resin was washed with additional CH_2Cl_2 (5 volumes/ gram of initial dried peptide-resin) to fully extract the cleaved peptide from the resin. Solvents in the combined filtrates were evaporated by rotary evaporation and the solids dried in vacuo overnight. The solids were then reconstituted in CH_2Cl_2 , evaporated by rotary evaporation and dried in vacuo overnight again to remove residual entrapped TFE.

Macrocyclization procedure (syringe pump)

Three coupling agents (DEPBT, HATU, and TBTU) were used at 0.5 to 0.75 equiv each. These coupling agents were dissolved in 3/4 of a calculated volume of dry methylene chloride that would give a 0.005–0.007 M overall concentration when included in the volume used for the deprotected peptide. The crude, dry, double deprotected peptide (free acid and free amine) was dissolved in the other 1/4 solvent volume of methylene chloride. DIPEA (8 equiv) was then added to the solution containing coupling reagents dissolved in methylene chloride. The double deprotected peptide was then added to the bulk solution dropwise using a syringe pump at a rate of 30 mL/h. The reaction was monitored via LCMS and generally complete in 1–2 h. Upon completion, the reaction was worked up by washing with aqueous HCl (pH 1) and saturated sodium bicarbonate. After back extraction of aqueous layers with large quantities of CH_2Cl_2 , the organic layers were combined, dried, filtered and concentrated. All macrocycles were first purified by flash column chromatography using an ethyl acetate/hexane gradient on silica gel. Finally, when necessary, reversed-phase HPLC was used for additional purification using a gradient of acetonitrile and deionized water with 0.1% TFA.

Benylation of compounds 2-T-II and 2-T-III

The purified macrocycle was benzylation using 2.0–5.0 equiv of benzyl bromide and 2.0–5.0 equiv of sodium hydride (60% w/w in mineral oil) in 0.1M of dry tetrahydrofuran. Under dry conditions, the macrocycle was dissolved in THF. Sodium hydride was added and allowed to dissolve, followed by the addition of benzyl bromide. The reaction was monitored by LCMS and was complete in 6–12 hours. Upon completion, the reaction was worked up with 2 treatments of deionized water. After back extraction of the aqueous layers with large quantities of CH_2Cl_2 , the organic layers were combined, dried, filtered and concentrated *in vacuo*. Benzylation macrocycles were first purified by flash column chromatography using an ethyl acetate/hexane gradient on silica gel. Finally, when necessary, reverse-phase HPLC was used for additional purification using a gradient of acetonitrile and deionized water with 0.1% TFA.

Deprotection of lysine amine (removal of Boc). Boc protected lysine was deprotected using 20% trifluoroacetic acid and 80% methylene chloride with 1 eq of anisole at 0.1M overall concentration. The reaction mixture was

stirred under normal atmospheric pressure and room temperature for 45 minutes and was monitored by TLC and LCMS. The final deprotected peptide was taken on to the biotinylation step without further purification.

Coupling of peg-biotin to free lysine-containing macrocycle. All biotin-coupling reactions were carried out using cyclized free-lysine (1.0 equivalent) and biotinylating reagent: NHS-dPEG-Biotin (1.5 equivalents), along with 8 equivalents of DIPEA in 0.1M methylene chloride. The solution was stirred at room temperature and reactions were monitored by TLC and LCMS. The reaction was usually complete in 2-8 hours. Reverse-phase HPLC was used for purification using a gradient of acetonitrile and DI water with 0.1% TFA.

METHODS OF CHROMATOGRAPHIC PURITY

Method A

Instrument: Agilent 1200 Series HPLC
Agilent 62440A LC/MSD Trap

Column: Zorbax SB-C18
2.1x30mm 3.5-Micron

Mobile Phase A: 0.1% (v/v) formic acid, 100% (v/v) water

Mobile Phase B: 0.1% (v/v) formic acid, 100% (v/v) acetonitrile

Gradient:	Time (min)	Profile %A	Profile %B
	0	80	20
	4.5	10	90
	4.6	10	90
	7.0	85	15

Flow Rate: 1.0 ml/min

Injection: 4µL

Solvent: 100% Methanol

Method B

Instrument: Waters Flex Inject
Waters 2487 Dual λ Absorbance Detector

Column: Symmetry C₁₈ 3.5µm
4.6x75mm Column

Mobile Phase A: 0.1% (v/v) Trifluoroacetic acid, 100% (v/v) water

Mobile Phase B: 0.1% (v/v) Trifluoroacetic acid, 100% (v/v) acetonitrile

λ₁: 215nm


λ₂: 222nm

Gradient:	Time (min)	Profile %A	Profile %B
	0	70	30
	4.00	0	100
	13.00	0	100
	15.00	70	30
	16.00	70	30

Flow rate: 0.50 ml/min


Injection: 20 μ L


Solvent: 100% Methanol



Display Report - All Windows Selected Analysis




Analysis Name: MP_202_LP.D **Instrument:** Agilent 6330 Ion Trap **Print Date:** 9/17/2010 2:38:25 PM
Method: SANA.M **Operator:** sdsu **Acq. Date:** 9/17/2010 2:23:38 PM
Sample Name: MP_202_LP
Analysis Info:



¹H NMR Cyclized Pentapeptide 1-T-II: *Phe-Lys(Cbz)-Val-Leu-Leu*

Display Report - All Windows Selected Analysis

Analysis Name: MNP_202_P_B.D **Instrument:** Agilent 6330 Ion Trap **Print Date:** 11/9/2010 6:17:08 PM
Method: SANA.M **Operator:** sdsu **Acq. Date:** 11/9/2010 6:05:41 PM
Sample Name: mnp_202_p_B
Analysis Info:




SDSU

Project Name: Defaults
Reported by User: System

1/Breeze


SAMPLE INFORMATION


Sample Name:	mnp_202_ss_pB	Acquired By:	System
Sample Type:	Unknown	Sample Set Name:	
Vial:	1	Acq. Method:	primary_sanA_ss_ACN
Injection #:	3	Date Acquired:	11/12/2010 10:50:36 AM
Run Time:	16.00 Minutes	Injection Volume:	100.00 ul



Channel: 2487Channel 1 Channel Desc.: Processing Method: *
Channel: 2487Channel 2 Channel Desc.: Processing Method: *



Peak Name	RT (min)	Area (V*sec)	% Area	Height (V)	Amount	Units
1	****	****	****	****	****	****
2	****	****	****	****	****	****



¹H NMR Cyclized Pentapeptide 1-T-II: *Phe-Lys-Val-Leu-Leu*

Display Report - All Windows Selected Analysis

Analysis Name: MNP_203A_01.D **Instrument:** Agilent 6330 Ion Trap **Print Date:** 11/24/2010 8:51:23 PM
Method: SANA.M **Operator:** sdsu **Acq. Date:** 11/24/2010 8:29:36 PM
Sample Name: mnp_203A_01
Analysis Info:




SDSU

Project Name: Defaults
 Reported by User: System

Breeze


SAMPLE INFORMATION


Sample Name:	mnp_203_ss_final	Acquired By:	System
Sample Type:	Unknown	Sample Set Name:	
Vial:	1	Acq. Method:	primary_sanA_ss_ACN
Injection #:	12	Date Acquired:	12/1/2010 4:52:52 PM
Run Time:	16.00 Minutes	Injection Volume:	100.00 ul



Channel: 2487Channel 1 Channel Desc.: Processing Method: *
 Channel: 2487Channel 2 Channel Desc.: Processing Method: *



Peak Name	RT (min)	Area (V*sec)	% Area	Height (V)	Amount	Units
1 ****	****	****	****	****	****	****
2 ****	****	****	****	****	****	****



¹H NMR Biotinylated Pentapeptide 1-T-II: *Phe-Lys(Peg-biotin)-Val-Leu-Leu*

Display Report - All Windows Selected Analysis

Analysis Name: MNP_203_TAG_ **Instrument:** Agilent 6330 Ion Trap **Print Date:** 5/26/2011 3:16:03 PM
Method: SANA.M A.D **Operator:** sdsu **Acq. Date:** 2/8/2011 4:47:59 PM
Sample Name: mnp_203_tag_A
Analysis Info:



SDSU

Project Name: Defaults

Reported by User: System

Breeze

SAMPLE INFORMATION

Sample Name: mnp_ss_203tag_final

Acquired By: System

Sample Type: Unknown

Sample Set Name:

Vial: 1


Acq. Method: primary_sanA_ss_ACN

Injection #: 142

Date Acquired: 2/18/2011 2:38:00 PM


Run Time: 16.00 Minutes


Injection Volume: 60.00 ul



— Channel: 2487Channel 1 Channel Desc.: Processing Method: *
— Channel: 2487Channel 2 Channel Desc.: Processing Method: *

	Peak Name	RT (min)	Area (V*sec)	% Area	Height (V)	Amount	Units
1	****	****	****	****	****	****	****
2	****	****	****	****	****	****	****








^1H NMR Double Deprotected Pentapeptide 1-T-III: *HO-Leu-Phe-Leu-Lys(Cbz)-Leu-NH₂*

Display Report - All Windows Selected Analysis


Analysis Name: MNP_204LP_01. **Instrument:** Agilent 6330 Ion Trap **Print Date:** 11/19/2010 5:26:42 AM
Method: SANA.M D **Operator:** sdsu **Acq. Date:** 10/1/2010 11:59:00 AM
Sample Name: mnp_204LP_01
Analysis Info:



¹H NMR Cyclized Pentapeptide 1-T-III: *Phe-Leu-Lys(Cbz)-Leu-Leu*

Display Report - All Windows Selected Analysis

Analysis Name: MNP_204_FINAL **Instrument:** Agilent 6330 Ion Trap **Print Date:** 11/24/2010 9:00:11 PM
Method: SANA.M .D **Operator:** sdsu **Acq. Date:** 11/24/2010 8:48:53 PM
Sample Name: mnp_204_final
Analysis Info:




SDSU


Project Name: Defaults
Reported by User: System


Breeze

SAMPLE INFORMATION

Sample Name: mnp_204_ss_final
Sample Type: Unknown
Vial: 1
Injection #: 10
Run Time: 16.00 MinutesAcquired By: System
Sample Set Name:
Acq. Method: primary_sanA_ss_ACN
Date Acquired: 12/1/2010 4:06:36 PM
Injection Volume: 100.00 ulChannel: 2487Channel 1 Channel Desc.: Processing Method: *
Channel: 2487Channel 2 Channel Desc.: Processing Method: *

	Peak Name	RT (min)	Area (V*sec)	% Area	Height (V)	Amount	Units
1	****	****	****	****	****	****	****
2	****	****	****	****	****	****	****






S24

Display Report - All Windows Selected Analysis

Analysis Name: MNP_205_01.D **Instrument:** Agilent 6330 Ion Trap **Print Date:** 11/24/2010 9:18:38 PM
Method: SANA.M **Operator:** sdsu **Acq. Date:** 11/24/2010 9:08:09 PM
Sample Name: mnp_205_01
Analysis Info:




SDSU

Project Name: Defaults
Reported by User: System

1/Breeze


SAMPLE INFORMATION

Sample Name:	mnps_205_ss_final	Acquired By:	System
Sample Type:	Unknown	Sample Set Name:	
Vial:	1	Acq. Method:	primary_sanA_ss_ACN
Injection #:	16	Date Acquired:	12/1/2010 6:24:25 PM
Run Time:	16.00 Minutes	Injection Volume:	100.00 ul





Channel: 2487Channel 1 Channel Desc.: Processing Method: *
Channel: 2487Channel 2 Channel Desc.: Processing Method: *

Peak Name	RT (min)	Area (V*sec)	% Area	Height (V)	Amount	Units
1	****	****	****	****	****	****
2	****	****	****	****	****	****



Display Report - All Windows Selected Analysis

Analysis Name: LDA_III_90_F14. **Instrument:** Agilent 6330 Ion Trap **Print Date:** 12/13/2010 11:11:19 AM
Method: SANA.M D **Operator:** sdsu **Acq. Date:** 12/10/2010 1:07:27 PM
Sample Name: LDA_III_90_f14
Analysis Info:






Leu

¹H NMR Biotinylated Pentapeptide 1-T-III: *Phe-Leu-Lys(Peg-biotin)-Leu-Leu*

Display Report - All Windows Selected Analysis



Analysis Name: JBK_145T1_LP.D **Instrument:** Agilent 6330 Ion Trap **Print Date:** 12/7/2010 10:17:34 AM
Method: SANA.M **Operator:** sdsu **Acq. Date:** 6/28/2010 10:35:16 AM
Sample Name: jbk_145T1_lp
Analysis Info:



¹H NMR Cyclized Pentapeptide 2-T-I: (2R, 3R) β-OH-Phe-Leu-N-Me-Val-D-Leu-D-Phe



Display Report - All Windows Selected Analysis


Analysis Name: JBK_196B.D **Instrument:** Agilent 6330 Ion Trap **Print Date:** 12/7/2010 10:00:16 AM
Method: SANA.M **Operator:** sdsu **Acq. Date:** 11/18/2010 4:02:48 AM
Sample Name: jbk_196b
Analysis Info:



Display Report - All Windows Selected Analysis


Analysis Name: LDA_III_128_F2 **Instrument:** Agilent 6330 Ion Trap **Print Date:** 4/29/2011 1:39:40 PM
Method: SANA.M 5.D **Operator:** sdsu **Acq. Date:** 3/15/2011 8:39:26 PM
Sample Name: LDA_III_128_f25
Analysis Info:







¹H NMR Cyclized Pentapeptide 2-T-II: (2R, 3R)(2S,3S) β-OBn-Phe-Lys(Boc)-N-Me-Val-D-Leu-D-Phe


Analysis Name: MNP_145_X_293 **Instrument:** Agilent 6330 Ion Trap **Print Date:** 5/13/2011 11:41:36 AM
Method: SANA.M 0.D **Operator:** sdsu **Acq. Date:** 5/6/2011 2:56:31 PM
Sample Name: mnp_145_x_2930
Analysis Info:



Display Report - All Windows Selected Analysis



Analysis Name: MNP_145T2_X_ **Instrument:** Agilent 6330 Ion Trap **Print Date:** 5/23/2011 3:30:54 PM
Method: SANA.M DEP.D **Operator:** sdsu **Acq. Date:** 5/23/2011 3:24:09 PM
Sample Name: mnp_145t2_x_dep
Analysis Info:







Display Report - All Windows Selected Analysis

Analysis Name: LDA_III_130_14 **Instrument:** Agilent 6330 Ion Trap **Print Date:** 4/21/2011 6:13:21 PM
Method: SANA.M 5-TAG2.D **Operator:** sdsu **Acq. Date:** 4/21/2011 5:15:17 PM
Sample Name: LDA_III_130_145-tag2
Analysis Info:




Display Report - All Windows Selected Analysis


Analysis Name: LDA_145-TAG3_ **Instrument:** Agilent 6330 Ion Trap **Print Date:** 4/18/2011 5:40:21 PM
Method: SANA.M DD.D **Operator:** sdsu **Acq. Date:** 12/15/2010 11:22:20 AM
Sample Name: LDA_145-tag3_dd
Analysis Info:




LCMS Double Deprotected Pentapeptide 2-T-III: *OH-Leu-N-Me-Lys(Boc)-D-Leu-D-Phe-(2R,3R)(2S,3S)-β-OH-Phe-NH₂*



Analysis Name: LDA_III_116_PO **Instrument:** Agilent 6330 Ion Trap **Print Date:** 4/18/2011 5:38:44 PM
Method: SANA.M ST WASH.D **Operator:** sdsu **Acq. Date:** 1/17/2011 11:52:38 AM
Sample Name: LDA_III_116_post wash
Analysis Info:







S40

Display Report - All Windows Selected Analysis


Analysis Name: LDA_145-T3_UN **Instrument:** Agilent 6330 Ion Trap **Print Date:** 4/25/2011 4:44:17 PM
Method: SANA.M K.D **Operator:** sdsu **Acq. Date:** 4/25/2011 3:59:12 PM
Sample Name: LDA_145-t3_unk
Analysis Info:




¹H NMR Biotinylated Pentapeptide 2-T-III: (2R,3R) β -OBn-Phe-Leu-NMe-Lys(Biotin)-

Display Report - All Windows Selected Analysis

Analysis Name: LDA_III_122_4M **Instrument:** Agilent 6330 Ion Trap **Print Date:** 2/21/2011 11:15:56 AM
Method: SANA.M G.D **Operator:** sdsu **Acq. Date:** 2/21/2011 11:01:48 AM
Sample Name: LDA_III_122_4mg
Analysis Info:



DLeu

LCMS Biotinylated Pentapeptide 2-T-III: (2R,3R) β -OBn-Phe-Leu-N-Me-Lys(Peg-biotin)-D-Leu-D-Phe

SDSU


Project Name: Defaults

Reported by User: System

Breeze

SAMPLE INFORMATION


Sample Name:	LDA_145-t3_peg-biotin	Acquired By:	System
Sample Type:	Unknown	Sample Set Name:	
Vial:	1	Acq. Method:	primary_sanA_ss_ACN
Injection #:	177	Date Acquired:	3/2/2011 2:47:17 PM
Run Time:	16.00 Minutes	Injection Volume:	25.00 ul



Channel: 2487Channel 1 Channel Desc.: Processing Method: *

Channel: 2487Channel 2 Channel Desc.: Processing Method: *

	Peak Name	RT (min)	Area (V*sec)	% Area	Height (V)	Amount	Units
1	****	****	****	****	****	****	****
2	****	****	****	****	****	****	****



Report Method: Injection Summary Report Printed 3:03:29 PM 3/2/2011

Page: 1 of 1

HPLC Biotinylated Pentapeptide 2-T-III: (2R,3R) β -OBn-Phe-Leu-N-Me-Lys(Peg-biotin)-D-Leu-D-Phe